- Home
- IONS vs CSWI Comparison
IONS vs CSWI Comparison
Compare IONS & CSWI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- CSWI
- Stock Information
- Founded
- IONS 1989
- CSWI 2014
- Country
- IONS United States
- CSWI United States
- Employees
- IONS N/A
- CSWI N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- CSWI Home Furnishings
- Sector
- IONS Health Care
- CSWI Industrials
- Exchange
- IONS Nasdaq
- CSWI Nasdaq
- Market Cap
- IONS 6.0B
- CSWI 4.9B
- IPO Year
- IONS 1991
- CSWI N/A
- Fundamental
- Price
- IONS $27.26
- CSWI $295.91
- Analyst Decision
- IONS Buy
- CSWI Buy
- Analyst Count
- IONS 19
- CSWI 4
- Target Price
- IONS $59.24
- CSWI $384.67
- AVG Volume (30 Days)
- IONS 1.6M
- CSWI 132.8K
- Earning Date
- IONS 05-06-2025
- CSWI 05-22-2025
- Dividend Yield
- IONS N/A
- CSWI 0.32%
- EPS Growth
- IONS N/A
- CSWI 33.74
- EPS
- IONS N/A
- CSWI 8.33
- Revenue
- IONS $705,138,000.00
- CSWI $858,612,000.00
- Revenue This Year
- IONS N/A
- CSWI $13.33
- Revenue Next Year
- IONS $25.71
- CSWI $8.17
- P/E Ratio
- IONS N/A
- CSWI $35.52
- Revenue Growth
- IONS N/A
- CSWI 10.41
- 52 Week Low
- IONS $27.20
- CSWI $226.05
- 52 Week High
- IONS $52.34
- CSWI $436.50
- Technical
- Relative Strength Index (RSI)
- IONS 27.86
- CSWI 45.71
- Support Level
- IONS $31.04
- CSWI $282.23
- Resistance Level
- IONS $33.76
- CSWI $314.79
- Average True Range (ATR)
- IONS 1.28
- CSWI 9.06
- MACD
- IONS -0.52
- CSWI 1.67
- Stochastic Oscillator
- IONS 0.86
- CSWI 42.02
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
About CSWI CSW Industrials Inc.
CSW Industrials Inc is a diversified industrial growth company with well-established, scalable platforms and domain expertise across three segments, Contractor Solutions, Engineered Building Solutions, and Specialized Reliability Solutions. The company's Contractor Solutions segment involves manufacturing efficient and performance-enhancing products for residential and commercial HVAC/R and plumbing applications, which are designed for professional end-use customers. Majority of the company revenue is generated from Contractor Solutions segment from U.S. markets.